Is There a Future in B Cell Medicine?

We are currently developing a pipeline in rare disease and oncology. I can also tell you that we are aiming to have our first program in the clinic in 2024. And it really will be in 2023 that we start to both become public about the indication for the lead. Our lead program will intentionally be autologous. That's where you're going to take the cells out of an individual patient, make the edits, and then re-infuse their own cells back into them as the therapy.